Skip to main content

Table 1 Baseline characteristics by gender of all COVID-19 cases referred to healthcare centres in Mashhad City from Feb 14, to May 11, 2020

From: Epidemiological characteristics and initial spatiotemporal visualisation of COVID-19 in a major city in the Middle East

Reference

All patients

Males

Females

p-value

Number of patients (%)

4000 (100)

2352 (58.8)

1648 (41.2)

 

Median age of the patients

57.0 years

56 .0 years

58 .0 years

0.0104*

Age range

39.0–71.0

39.0–70.0

39.0–73.0

Days from onset to hospital admission

2.0

2.0

2.0

0.9783

Range of days

1.0–4.0

1.0–4.0

0.0–4.0

Days from hospital admission to outcome

5.0

5.0

5.0

0.4751

Range of days

2.0–8.0

2.0–8.0

2.0–8.0

Demographics & clinical characteristics

Number (%)

Number (%)

Number (%)

 

Co-morbidity

 Diabetes

491 (12.27)

252 (10.71)

239 (14.50)

0.0003*

 CVD

805 (20.12)

404 (17.2)

401 (24.3)

< 0.0001*

 Liver disorders

112 (2.80)

61 (2.59)

51 (3.09)

0.3444

 CRD

155 (3.87)

95 (4.04)

60 (3.64)

0.5206

 Nervous diseases

99 (2.47)

64 (2.72)

35 (2.12)

0.2314

 COPD

236 (5.90)

115 (4.89)

121 (7.34)

0.0011*

 Malignancy (any)

99 (2.47)

59 (2.50)

40 (2.42)

0.8706

Initial symptoms

 Fever

2177 (54.42)

1308 (55.61)

869 (52.73)

0.0716

 Cough

2377 (59.42)

1383 (58.80)

994 (60.31)

0.337

 Dyspnoea

2777 (69.42)

1606 (68.28)

1171 (71.05)

0.0609

 Weakness

778 (19.45)

452 (19.21)

326 (19.78)

0.6574

 Myalgia

574 (14.35)

331 (14.07)

243 (14.74)

0.5507

 Dizziness

338 (8.45)

206 (8.75)

132 (8.0)

0.4020

 Sore throat

434 (10.85)

262 (11.13)

172 (10.43)

0.4819

 Sputum

74 (1.85)

37 (1.57)

37 (2.24)

0.1206

 Diarrhoea

137 (3.42)

79 (3.35)

58 (3.51)

0.7834

 Nausea or vomiting

332 (8.30)

182 (7.74)

150 (9.10)

0.1238

 Headache

325 (8.12)

184 (7.82)

141 (8.55)

0.4038

 Chest pain

318 (7.95)

181 (7.70)

137 (8.30)

0.4773

 Abdominal pain

70 (1.75)

32 (1.36)

38 (2.30)

0.0248*

 Arthralgia

235 (5.87)

133 (5.65)

102 (6.19)

0.4792

 Pharyngitis

49 (1.22)

27 (1.14)

22 (1.33)

0.5967

 Conjunctivitis

30 (0.75)

17 (0.72)

13 (0.78)

0.8117

 Abnormal chest X-ray

1059 (26.47)

617 (26.23)

442 (26.82)

0.6786

End-points

 ICU admission

502 (12.55)

307 (13.05)

195 (11.83)

0.2516

 Ventilator

772 (19.30)

449 (19.09)

323 (19.59)

0.6878

 Coma

24 (0.60)

16 (0.68)

8 (0.48)

0.4322

Exposure history (last 14 days)

 Travel

83 (2.07)

58 (2.46)

25 (1.51)

0.0382*

 Exposed at medical centres

323 (8.07)

185 (7.86)

138 (8.37)

0.5615

 Exposed to possibly infected individuals

267 (6.68)

155 (6.59)

112 (6.79)

0.7973

 Exposed to animals

175 (4.37)

118 (5.02)

57 (3.46)

0.0177*

 Being healthcare staff

281 (7.03)

158 (6.71)

123 (7.46)

0.3636

Disease severity

0.0404*

 General

3228 (80.70)

1927 (81.93)

1301 (78.94)

 Severe

748 (18.70)

414 (17.60)

334 (20.27)

 Critical

24 (0.60)

11 (0.47)

13 (0.79)

Disease outcome

0.0437*

 Non-survivor

707 (17.67)

430 (18.3)

277 (16.8)

 Survivor

2236 (55.90)

1334 (56.7)

902 (54.7)

 Ongoing care

1057 (26.43)

588 (25.0)

469 (28.5)

COVID-19 confirmation

0.0118*

 PCR confirmation

1325 (33.1)

816 (34.7)

509 (30.9)

 Clinical confirmation

2675 (66.9)

1536 (65.3)

1139 (69.1)

  1. CVD Cardiovascular Diseases, CRD Chronic Renal Diseases, COPD Chronic Obstructive Pulmonary Diseases, ICU Intensive Care Unit. *Significant values